Background: Augmented reality (AR) and mixed reality (MR) promise to enhance anatomical understanding, spatial orientation, and workflow in cardiac surgery. Their clinical adoption remains limited and the translational path is incompletely defined. Methods: A PubMed search was conducted by two independent reviewers from database inception through July 2025 and identified peer-reviewed, English-language articles describing peri- or intra-operative AR/MR applications in cardiac surgery. Relevant clinical, preclinical, technical, and review articles were selected for inclusion based on scope and content. Given the narrative approach and heterogeneity across studies, findings were synthesized qualitatively into application domains. Results: Fourteen studies were included. Five domains emerged: (1) preoperative planning and patient-specific modelling—MR enhanced spatial orientation and planning for minimally invasive and valve procedures; (2) intraoperative navigation and visualization—AR improved targeting and interpretation with preclinical overlay errors ≈ 5 mm; (3) physiological/functional guidance—thermographic AR detected ischemia in vivo with strong correlation to invasive thermometry; (4) robotic integration and workflow optimization—AR-guided port placement and stepwise robotic adoption supported the feasibility of totally endoscopic CABG; (5) AR-based early rehabilitation. Conclusions: Early clinical and preclinical evidence supports AR/MR feasibility and utility for visualization and orientation in cardiac surgery. Priorities include deformable, motion-compensated registration, ergonomic integration with robotic platforms, and multicentre trials powered for operative efficiency and patient outcomes.
Anesthesiologic management of Transcatheter Aortic Valve Implantation (TAVI) is a key factor in procedural success and effectiveness. Although general anesthesia was the main anesthesiologic approach during the early years of the development of TAVI, over the last decade, there has been a shift towards sedation. Hemodynamic stability is the main concern of intraoperative anesthesiologic management. Preprocedural, multidisciplinary assessment of the patient is essential prior to TAVI and should include a full anesthesiologic evaluation. TAVI offers a number of advantages to patients and medical teams, but important accompanying complications and anesthesiologic risks remain. In this narrative review, all aspects of sedation in TAVI are presented and analyzed, including methods, patient selection, contraindications, drug administration, intraprocedural parameters, outcomes, and future developments in this field.
Aortic valve diseases affect a significant percentage of the population, and with the extension of survival expectancy, they are expected to increase furthermore. Surgical treatment of aortic valve diseases mainly includes valve replacement and, rarely, its repair. The technology of both surgical and transcatheter valves is evolving, and new prosthetic valves with improved characteristics are available, e.g., longer lifespan, faster implantation, better hemodynamic performance with better effective orifice area, suitable for small aortic annuli, etc. Minimally invasive surgical techniques are constantly evolving and spreading. New access sites are used for transcatheter valve implantation. The Heart Team determines the most appropriate intervention for each patient based on their anatomical and clinical profiles, aiming to optimize long-term outcomes.
Background: The widespread use of fluoroquinolones has been associated with the formation, dissection, and rupture of aortic aneurysms. Arterial biomarkers are established predictors of cardiovascular events. The present study was designed to investigate the effect of quinolones on arterial stiffness and aortic size for the first time. Methods: We studied 28 subjects receiving short-term (<15 days) antibiotic therapy involving quinolones and 27 age- and sex-matched subjects receiving an alternative to quinolone antibiotics. The follow-up period was approximately 2 months. The study’s primary endpoint was the carotid–femoral pulse wave velocity (cfPWV) difference between the two groups 2 months after therapy initiation. Secondary endpoints were the augmentation index corrected for heart rate (AIx@75) and sonographically assessed aortic diameters 2 months after the initial treatment. Results: Subjects had similar values of arterial biomarkers, blood pressure measurements, and aortic diameters at baseline. At follow-up, no significant change was observed between the two groups regarding the hemodynamic parameters and arterial biomarkers (p > 0.05 for all), i.e., cfPWV (7.9 ± 2.6 m/s for the control group vs. 8.1 ± 2.4 m/s for the fluoroquinolones group; p = 0.79), AIx@75 (22.6 ± 9.0% for the control group vs. 26.6 ± 8.1% for the fluoroquinolones group; p = 0.09), and aortic diameters. Conclusions: To our knowledge, FRAGILES is the first study to provide insights into the possible effects of fluoroquinolones on arterial biomarkers, showing that, at least in the short term, treatment with fluoroquinolones does not affect aortic function and diameter.
Background/Objectives: Minimally invasive (MIS) mitral valve surgery has been proven to be a safe and effective alternative to median sternotomy (ST), with advantages in postoperative recovery and morbidity. However, its role in the setting of infective endocarditis (IE) remains uncertain. This meta-analysis aims to evaluate the outcomes of MIS in mitral valve surgery for infective endocarditis. Methods: A PRISMA-compliant search for studies including patients undergoing MIS for mitral valve IE was performed through 14 January 2026, in PubMed, Scopus and Cochrane. Time-to-event data were reconstructed from published Kaplan–Meier curves. A secondary comparative analysis focusing on MIS versus ST techniques was conducted. Results: Fourteen retrospective studies comprising 949 patients were analyzed. In the MIS cohort, early mortality was 4.2% (95%CI: 1.8%, 7.4%). Overall survival was 86.7% at 1 year, 75.2% at 5 years and 56.2% at 10 years. Freedom from IE-related reoperation remained high at 97.5%, 95.9%, and 90.7% at 1, 5, and 10 years, respectively. Mitral valve repair was performed in 52.5% of patients. In secondary comparative analyses, overall survival at 4-year follow-up was not different between MIS and ST [HR: 0.82 (95%CI: 0.43, 1.57), p = 0.55]. MIS was associated with a significantly shorter intensive care unit (ICU) stay [MD: −1.52 days (95%CI: −2.08, −0.97), p < 0.01]. Conclusions: MIS for mitral valve IE is associated with favorable early and long-term outcomes, comparable survival with sternotomy, and reduced ICU stay. These findings suggest that MIS may be considered as a feasible and potentially effective alternative for the management of mitral valve IE in carefully selected patients. Further prospective comparative studies are warranted.